- Silexion Therapeutics (Nasdaq:Slxn) He announced entry into definite agreements for the immediate performance of certain outstanding purchases to aggregates of 2.22 million shares that were originally issued in January 2025. years, they have an exercise of $ 1.35 / divided.
- The gross income from exercising the order is expected to be ~ 3.3 million dollars.
- The offer is expected to close or approximately 30. January 2025. January.
- SLXN intends to use net income from the offer as working capital for general corporate purposes.
- SLXN divides 34% of the post-market on Wednesday.
- Source: Press release